Halozyme Therapeutics, Inc. (NASDAQ:HALO)
CAPS Rating:
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
RSS Headlines
Fool UK
Recs
There are currently 1300 HALO shares in my "fund" with break-even of around 7.15 USD. http://caps.fool.com/Blogs/fund-trades/678775.
now 1100 shares in the fund with break-even of around 6.65 USD.
http://caps.fool.com/Blogs/fund-trades/705717.
http://twitter.com/portefeuillefun.